Ian Karp | SVP, IR & Corporate Communications |
John Leonard | President, CEO & Director |
David Lebwohl | EVP & Chief Medical Officer |
Laura Sepp-Lorenzino | EVP & Chief Scientific Officer |
John Hayes | Senior Director, Finance & Controller |
Glenn Goddard | EVP, CFO & Treasurer |
Swapnil Malekar | Piper Sandler & Co. |
Maurice Raycroft | Jefferies |
Dae Gon Ha | Stifel, Nicolaus & Company |
Salveen Richter | Goldman Sachs Group |
Joseph Thome | Cowen and Company |
Gena Wang | Barclays Bank |
Luca Issi | RBC Capital Markets |
Mani Foroohar | SVB Leerink |
Yanan Zhu | Wells Fargo Securities |
Jay Olson | Oppenheimer |
Good morning. My name is Drew, and I will be your conference operator today, and welcome to the Intellia Therapeutics First Quarter 2022 earnings conference call. [Operator Instructions]. At this time, I would like to turn it over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.